BeOne Medicines (BEIGF) Tax Provisions (2016 - 2026)

BeOne Medicines (BEIGF) has 11 years of Tax Provisions data on file, last reported at $31.9 million in Q1 2026.

• Tax Provisions for Q1 2026 came in at $31.9 million, up 62.29% year-over-year; the trailing twelve-month figure through Mar 2026 was $142.1 million (up 14.92% YoY), and the FY2025 annual result was $129.9 million, up 16.22% from the prior year.
• Tax Provisions retreated to $31.9 million in Q1 2026 per BEIGF's latest filing, from $82.7 million in the prior quarter.
• Over five years, Tax Provisions peaked at $82.7 million in Q4 2025 and troughed at $5.2 million in Q2 2025.
• A 5-year average of $21.9 million and a median of $14.4 million in 2022 frame the typical range for Tax Provisions.
• The sharpest annual moves came in 2022 and 2025: Tax Provisions jumped 3639.57% in 2022, then plunged 63.9% in 2025.
• A 5-year view of Tax Provisions shows it stood at $14.4 million in 2022, then grew by 16.78% to $16.8 million in 2023, then jumped by 296.46% to $66.5 million in 2024, then grew by 24.36% to $82.7 million in 2025, then sank by 61.5% to $31.9 million in 2026.
• Business Quant data shows BEIGF's Tax Provisions at $31.9 million in Q1 2026, $82.7 million in Q4 2025, and $22.3 million in Q3 2025.